RxDoctor Payments Data

Sameh Rizkalla, MD

Physical Medicine & Rehabilitation · Copley, OHNPI 1700829280

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $1,605 of the $2,043 with a category attached, or 78.6%. Davol Inc. accounts for 78.6% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $1,789 and has fallen 88.7% since, to $203 in 2025.

$2,043in general payments, 2019–2025

Across 14 payments — averaging $145.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Davol Inc.$2K
  • Madrigal Pharmaceuticals$151
  • Takeda Pharmaceuticals U.S.A., Inc.$135
  • Aimmune Therapeutics, Inc.$61
  • Johnson & Johnson$51
  • Dilon Technologies, Inc.$22
  • plus $18 from 1 others

What the payments were for

  • Consulting fees$1,60579%
  • Food & beverage$43821%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,043 in reported general payments places this provider in the 80th percentile of 332 physical medicine & rehabilitation providers in Ohio.

See all physical medicine & rehabilitation providers in Ohio

Medicare billing

Part B allowed, 2024
$134,643
Medicare patients
304
Services billed
1,557

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban48$23,349
LantusInsulin Glargine,hum.Rec.Anlog16$991
Pantoprazole Sodium87$654
Atorvastatin Calcium101$610
Albuterol Sulfate HfaAlbuterol Sulfate29$599
Gabapentin57$577
Insulin Lispro20$480
Ondansetron OdtOndansetron29$372
Metoprolol Succinate37$301
Oxycodone Hcl62$297
Torsemide21$295
Diclofenac Sodium12$276
Levothyroxine Sodium41$215
Aripiprazole13$212
Mirtazapine15$189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCInsulin Lispro$18$48020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 332 physical medicine & rehabilitation providers in Ohio.

Other physical medicine & rehabilitation in Copley

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →